Papers - Sampetrean, Oltea

Visualization of spatiotemporal dynamics of human glioma stem cell invasion

Tamura R., Miyoshi H., Sampetrean O., Shinozaki M., Morimoto Y., Iwasawa C., Fukaya R., Mine Y., Masuda H., Maruyama T., Narita M., Saya H., Yoshida K., Okano H., Toda M.

Molecular Brain (Molecular Brain)  12 ( 1 )  2019.05

　View Summary

Glioblastoma exhibits phenotypic and genetic heterogeneity, aggressive invasiveness, therapeutic resistance, and tumor recurrence, which can be explained by the existence of glioma stem cells (GSCs). In this study, we visualized the spatiotemporal dynamics of invasion of human GSCs in an orthotopic xenograft mouse model using time-lapse imaging of organotypic brain slice cultures and three-dimensional imaging of optically cleared whole brains. GSCs implanted in the striatum exhibited directional migration toward axon bundles, perivascular area, and the subventricular zone around the inferior horn of the lateral ventricle. GSCs migrated in a helical pattern around axon bundles in the striatum and invaded broadly in both the rostral and caudal directions. GSCs in the corpus callosum migrated more rapidly and unidirectionally toward the contralateral side with pseudopod extension. These characteristics of GSC invasion shared histological features observed in glioblastoma patients. Spatiotemporal visualization techniques can contribute to the elucidation of the mechanisms underlying GSC invasion that may lead to the development of effective therapy for glioblastoma.

• Access to Document (DOI)

Tranilast inhibits the expression of genes related to epithelial-mesenchymal transition and angiogenesis in neurofibromin-deficient cells

Harigai R., Sakai S., Nobusue H., Hirose C., Sampetrean O., Minami N., Hata Y., Kasama T., Hirose T., Takenouchi T., Kosaki K., Kishi K., Saya H., Arima Y.

Scientific Reports (Scientific Reports)  8 ( 1 )  2018.12

　View Summary

© 2018 The Author(s). Neurofibromatosis type 1 (NF1) is caused by germline mutations in the NF1 gene and is characterized by café au lait spots and benign tumours known as neurofibromas. NF1 encodes the tumour suppressor protein neurofibromin, which negatively regulates the small GTPase Ras, with the constitutive activation of Ras signalling resulting from NF1 mutations being thought to underlie neurofibroma development. We previously showed that knockdown of neurofibromin triggers epithelial-mesenchymal transition (EMT) signalling and that such signalling is activated in NF1-associated neurofibromas. With the use of a cell-based drug screening assay, we have now identified the antiallergy drug tranilast (N-(3,4-dimethoxycinnamoyl) anthranilic acid) as an inhibitor of EMT and found that it attenuated the expression of mesenchymal markers and angiogenesis-related genes in NF1-mutated sNF96.2 cells and in neurofibroma cells from NF1 patients. Tranilast also suppressed the proliferation of neurofibromin-deficient cells in vitro more effectively than it did that of intact cells. In addition, tranilast inhibited sNF96.2 cell migration and proliferation in vivo. Knockdown of type III collagen (COL3A1) also suppressed the proliferation of neurofibroma cells, whereas expression of COL3A1 and SOX2 was increased in tranilast-resistant cells, suggesting that COL3A1 and the transcription factor SOX2 might contribute to the development of tranilast resistance.

• Access to Document (DOI)

CD44 variant inhibits insulin secretion in pancreatic β cells by attenuating LAT1-mediated amino acid uptake

Kobayashi N., Okazaki S., Sampetrean O., Irie J., Itoh H., Saya H.

Scientific Reports (Scientific Reports)  8 ( 1 )  2018.12

　View Summary

© 2018 The Author(s). CD44 variant (CD44v) contributes to cancer stemness by stabilizing the xCT subunit of system xc(-) and thereby promoting its glutamate-cystine antiporter activity. CD44 has also been implicated in autoimmune insulitis and inflammation in diabetic islets, but whether CD44v regulates insulin secretion has remained unclear. Here we show that CD44v inhibits insulin secretion by attenuating amino acid transport mediated by the L-type amino acid transporter LAT1. CD44v expression level was inversely related to insulin content in islets of normal and diabetic model mice. Knockdown of CD44 increased insulin secretion, the intracellular insulin level, and the transport of neutral amino acids mediated by LAT1 in Min6 cells. Attenuation of the uptake of neutral amino acids with a LAT inhibitor reduced insulin secretion and insulin content in Min6 cells, whereas overexpression of LAT1 increased insulin secretion. Moreover, inhibition of LAT1 prevented the increase in insulin secretion and content induced by CD44 depletion in Min6 cells. Our results thus implicate CD44v in the regulation of insulin secretion and reveal that amino acid transport is rate limiting for such secretion. They further suggest that amino acid transport mediated by LAT1 is a potential therapeutic target for diabetes.

• Access to Document (DOI)

Gold-nanofève surface-enhanced Raman spectroscopy visualizes hypotaurine as a robust anti-oxidant consumed in cancer survival

Shiota M., Naya M., Yamamoto T., Hishiki T., Tani T., Takahashi H., Kubo A., Koike D., Itoh M., Ohmura M., Kabe Y., Sugiura Y., Hiraoka N., Morikawa T., Takubo K., Suina K., Nagashima H., Sampetrean O., Nagano O., Saya H., Yamazoe S., Watanabe H., Suematsu M.

Nature Communications (Nature Communications)  9 ( 1 )  2018.12

　View Summary

© 2018 The Author(s). Gold deposition with diagonal angle towards boehmite-based nanostructure creates random arrays of horse-bean-shaped nanostructures named gold-nanofève (GNF). GNF generates many electromagnetic hotspots as surface-enhanced Raman spectroscopy (SERS) excitation sources, and enables large-area visualization of molecular vibration fingerprints of metabolites in human cancer xenografts in livers of immunodeficient mice with sufficient sensitivity and uniformity. Differential screening of GNF-SERS signals in tumours and those in parenchyma demarcated tumour boundaries in liver tissues. Furthermore, GNF-SERS combined with quantum chemical calculation identified cysteine-derived glutathione and hypotaurine (HT) as tumour-dominant and parenchyma-dominant metabolites, respectively. CD44 knockdown in cancer diminished glutathione, but not HT in tumours. Mechanisms whereby tumours sustained HT under CD44-knockdown conditions include upregulation of PHGDH, PSAT1 and PSPH that drove glycolysis-dependent activation of serine/glycine-cleavage systems to provide one-methyl group for HT synthesis. HT was rapidly converted into taurine in cancer cells, suggesting that HT is a robust anti-oxidant for their survival under glutathione-suppressed conditions.

• Access to Document (DOI)

Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate–sensitive glutamate receptor signaling

Suina K., Tsuchihashi K., Yamasaki J., Kamenori S., Shintani S., Hirata Y., Okazaki S., Sampetrean O., Baba E., Akashi K., Mitsuishi Y., Takahashi F., Takahashi K., Saya H., Nagano O.

Cancer Science (Cancer Science)  109 ( 12 ) 3874 - 3882 2018.12

ISSN  13479032

　View Summary

© 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. Autocrine and paracrine factors, including glutamate and epidermal growth factor (EGF), are potent inducers of brain tumor cell invasion, a pathological hallmark of malignant gliomas. System xc(–) consists of xCT and CD98hc subunits and functions as a plasma membrane antiporter for the uptake of extracellular cystine in exchange for intracellular glutamate. We previously showed that the EGF receptor (EGFR) interacts with xCT and thereby promotes the activity of system xc(–) in a kinase-independent manner, resulting in enhanced glutamate release in glioma cells. However, the molecular mechanism underlying EGFR-mediated glioma progression in a glutamate-rich microenvironment has remained unclear. Here we show that the GluN2B subunit of the N-methyl-d-aspartate–sensitive glutamate receptor (NMDAR) is a substrate of EGFR in glioma cells. In response to EGF stimulation, EGFR phosphorylated the COOH-terminal domain of GluN2B and thereby enhanced glutamate-NMDAR signaling and consequent cell migration in EGFR-overexpressing glioma cells. Treatment with the NMDAR inhibitor MK-801 or the system xc(–) inhibitor sulfasalazine suppressed EGF-elicited glioma cell migration. The administration of sulfasalazine and MK-801 also synergistically suppressed the growth of subcutaneous tumors formed by EGFR-overexpressing glioma cells. Furthermore, shRNA-mediated knockdown of xCT and GluN2B cooperatively prolonged the survival of mice injected intracerebrally with such glioma cells. Our findings thus establish a central role for EGFR in the signaling crosstalk between xCT and GluN2B-containing NMDAR in glioma cells.

• Access to Document (DOI)

HER2 heterogeneity is associated with poor survival in HER2-positive breast cancer

Hosonaga M., Arima Y., Sampetrean O., Komura D., Koya I., Sasaki T., Sato E., Okano H., Kudoh J., Ishikawa S., Saya H., Ishikawa T.

International Journal of Molecular Sciences (International Journal of Molecular Sciences)  19 ( 8 )  2018.08

ISSN  16616596

　View Summary

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. Intratumoral human epidermal growth factor receptor 2 (HER2) heterogeneity has been reported in 16–36% of HER2-positive breast cancer and its clinical impact is under discussion. We examined the biological effects of HER2-heterogeneity on mouse models and analyzed metastatic brains by RNA sequence analysis. A metastatic mouse model was developed using 231-Luc (triple negative cells) and 2 HER2-positive cell lines, namely, HER2-60 and HER2-90 which showed heterogeneous and monotonous HER2 expressions, respectively. Metastatic lesions developed in 3 weeks in all the mice injected with HER2-60 cells, and in 69% of the mice injected with HER2-90 and 87.5% of the mice injected with 231-Luc. The median survival days of mice injected with 231-Luc, HER2-60, and HER2-90 cells were 29 (n = 24), 24 (n = 22) and 30 (n = 13) days, respectively. RNA sequence analysis showed that CASP-1 and its related genes were significantly downregulated in metastatic brain tumors with HER2-60 cells. The low expression of caspase-1 could be a new prognostic biomarker for early relapse in HER2-positive breast cancer.

• Access to Document (DOI)

Metabolic heterogeneity and plasticity of glioma stem cells in a mouse glioblastoma model

Shibao S., Minami N., Koike N., Fukui N., Yoshida K., Saya H., Sampetrean O.

Neuro-Oncology (Neuro-Oncology)  20 ( 3 ) 343 - 354 2018.02

ISSN  15228517

　View Summary

© 2018 The Author(s). Background. Glioblastomas have been shown to rely on glycolysis as an energy source. However, recent evidence suggests that at least a subset of glioma cells with stem cell-like properties can thrive on oxidative phosphorylation. It remains unclear whether both metabolic phenotypes support tumor propagation, if they are independent, and how stable they are. The present study investigated these questions with the use of isogenic murine glioma stem cells (GSCs). Methods. GSCs were established from tumors formed by Ink4a/Arf-null, H-RasV12-expressing glioma-initiating cells that differed in extracellular acidification potential. Metabolic characteristics of GSCs were determined by measurement of glucose, oxygen, and glutamine uptake, ATP content, and lactate production. Effects of metabolic inhibitors and changes in oxygen or nutrient availability on lactate production and tumorsphere growth were also determined. Results. GSCs were found either to consume more glucose and produce more lactate or to consume more oxygen and maintain a higher ATP content depending on the metabolic characteristics of the tumor cells of origin. The latter, mitochondrial-type GSCs increased lactate production after treatment with the oxidative phosphorylation inhibitor oligomycin or phenformin. Exposure to hypoxia also increased lactate production and expression of glycolysis-related enzymes and metabolites in mitochondrial-type GSCs in a reversible manner. Conclusions. Both glycolytic and mitochondrial-type energy production can sustain tumor propagation by isogenic GSCs. Whereas both phenotypes can be independent and stable, cells that rely on oxidative phosphorylation can also switch to a more glycolytic phenotype in response to metabolic stress, suggesting that plasticity is a further characteristic of GSC metabolism.

• Access to Document (DOI)

Convection-enhanced delivery of sulfasalazine prolongs survival in a glioma stem cell brain tumor model

Haryu S., Saito R., Jia W., Shoji T., Mano Y., Sato A., Kanamori M., Sonoda Y., Sampetrean O., Saya H., Tominaga T.

Journal of Neuro-Oncology (Journal of Neuro-Oncology)  136 ( 1 ) 23 - 31 2018.01

ISSN  0167594X

　View Summary

© 2017, Springer Science+Business Media, LLC. Expression of CD44 in glioma cells was previously correlated with tumor grade and is considered a stem cell marker. CD44 stabilizes the cystine–glutamate transporter (xCT) and inhibits apoptosis in cancer stem cells (CSCs). Recently it was found that Sulfasalazine (SSZ), an anti-inflammatory drug, acts as an inhibitor of xCT and therefore has potential as a targeted therapy for CSCs. In this study, we tested an efficacy of SSZ against glioma stem cell model developed in rats. As poor penetration of blood–brain barrier resulted in insufficient efficacy of systemic SSZ treatment, SSZ was delivered locally with convection-enhanced delivery (CED). In vitro, expression of CD44 in glioma cells and efficacy of SSZ against glioma cells and glioma stem cells were confirmed. SSZ demonstrated anti-proliferative activity in a dose dependent manner against these cells. This activity was partially reversible with the addition of antioxidant, N-acetyl-l-cysteine, to the medium. In vivo, CED successfully delivered SSZ into the rat brain parenchyma. When delivered at 5 mM concentration, which was the highest possible concentration when SSZ was dissolved in water, CED of SSZ resulted in almost no tissue damage. Against highly malignant bRiTs-G3 brain tumor xenografted rat model; the glioma stem cell model, CED of SSZ at 5 mM concentration induced apoptosis and prolonged survival. Consequently, CED of SSZ induced glioma stem cell death without evidence of tissue damage to normal brain parenchyma. This strategy may be a promising targeted treatment against glioma stem cells.

• Access to Document (DOI)

Modeling phenotypes of malignant gliomas

Sampetrean O., Saya H.

Cancer Science (Cancer Science)  109 ( 1 ) 6 - 14 2018.01

ISSN  13479032

　View Summary

© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. Malignant gliomas are primary tumors of the central nervous system characterized by diffuse infiltration into the brain and a high recurrence rate. Advances in comprehensive genomic studies have provided unprecedented insight into the genetic and molecular heterogeneity of these tumors and refined our understanding of their evolution from low to high grade. However, similar levels of phenotypic characterization are indispensable to understanding the complexity of malignant gliomas. Experimental glioma models have also achieved great progress in recent years. Advances in transgenic technologies and cell culture have allowed the establishment of mouse models that mirror the human disease with increasing fidelity and which support single-cell resolution for phenotypic analyses. Here we review the major types of preclinical glioma models, with an emphasis on how recent developments in experimental modeling have shed new light on two fundamental aspects of glioma phenotype, their cell of origin and their invasive potential.

• Access to Document (DOI)

Integrated analysis identifies different metabolic signatures for tumor-initiating cells in a murine glioblastoma model

Saga, Isako, Shibao, Shunsuke, Okubo, Jun, Osuka, Satoru, Kobayashi, Yusuke, Yamada, Sachiko, Fujita, Satoshi, Urakami, Kenichi, Kusuhara, Masatoshi, Yoshida, Kazunari, Saya, Hideyuki, Sampetrean, Oltea

NEURO-ONCOLOGY 16 ( 8 ) 1048 - 1056 2014.08

Research paper (scientific journal), Joint Work, Accepted,  ISSN  1522-8517

• Access to Document (DOI)

Characteristics of glioma stem cells

Sampetrean, Oltea, Saya, Hideyuki

BRAIN TUMOR PATHOLOGY 30 ( 4 ) 209 - 214 2013.10

Research paper (scientific journal),  ISSN  1433-7398

• Access to Document (DOI)

IGF1 Receptor Signaling Regulates Adaptive Radioprotection in Glioma Stem Cells

Osuka, Satoru, Sampetrean, Oltea, Shimizu, Takatsune, Saga, Isako, Onishi, Nobuyuki, Sugihara, Eiji, Okubo, Jun, Fujita, Satoshi, Takano, Shingo, Matsumura, Akira, Saya, Hideyuki

STEM CELLS 31 ( 4 ) 627 - 640 2013.04

Research paper (scientific journal), Accepted,  ISSN  1066-5099

• Access to Document (DOI)

Invasion Precedes Tumor Mass Formation in a Malignant Brain Tumor Model of Genetically Modified Neural Stem Cells

Sampetrean, Oltea, Saga, Isako, Nakanishi, Masaya, Sugihara, Eiji, Fukaya, Raita, Onishi, Nobuyuki, Osuka, Satoru, Akahata, Masaki, Kai, Kazuharu, Sugimoto, Hachiro, Hirao, Atsushi, Saya, Hideyuki

NEOPLASIA 13 ( 9 ) 784 - U28 2011.09

Research paper (scientific journal), Joint Work, Accepted,  ISSN  1522-8002

• Access to Document (DOI)

Maintenance of HCT116 colon cancer cell line conforms to a stochastic model but not a cancer stem cell model

Kai, Kazuharu, Nagano, Osamu, Sugihara, Eiji, Arima, Yoshimi, Sampetrean, Oltea, Ishimoto, Takatsugu, Nakanishi, Masaya, Ueno, Naoto T., Iwase, Hirotaka, Saya, Hideyuki

CANCER SCIENCE 100 ( 12 ) 2275 - 2282 2009.12

Research paper (scientific journal), Joint Work, Accepted,  ISSN  1347-9032

• Access to Document (DOI)

Reversible whole-organism cell cycle arrest in a living vertebrate

Sampetrean, Oltea, Iida, Shin-ichi, Makino, Shinji, Matsuzaki, Yuriko, Ohno, Kikuo, Saya, Hideyuki

CELL CYCLE 8 ( 4 ) 620 - 627 2009.02

Research paper (scientific journal), Joint Work, Accepted,  ISSN  1538-4101

Rapidly growing dysembryoplastic neuroepithelial tumor: Case report

Sampetrean, Oltea, Maehara, Taketoshi, Arai, Nobutaka, Nemoto, Tetsuo

NEUROSURGERY 59 ( 6 ) 1337 - 1338 2006.12

Research paper (scientific journal), Joint Work, Accepted,  ISSN  0148-396X

• Access to Document (DOI)